Novo Nordisk email archive

novonordisk.comBiopharmaceuticalsDK

Novo Nordisk is a prominent global healthcare company established in 1923 and headquartered in Denmark. Specializing in the production and distribution of insulin and other medications for diabetes, Novo Nordisk is committed to combating serious chronic diseases. With a workforce of approximately 66,000 employees, the company operates in 80 countries and markets its innovative products in around 170 nations. Novo Nordisk's mission revolves around driving change through scientific breakthroughs,

24 emails

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification email from Novo Nordisk

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI email from Novo Nordisk

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray email from Novo Nordisk

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook email from Novo Nordisk

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 email from Novo Nordisk

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation email from Novo Nordisk

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly email from Novo Nordisk

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved email from Novo Nordisk

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026 email from Novo Nordisk

Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Novo Nordisk to showcase new data across its haemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig email from Novo Nordisk

Novo Nordisk to showcase new data across its haemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

Novo Nordisk A/S: IT Security incident at Novo Nordisk email from Novo Nordisk

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK email from Novo Nordisk

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 email from Novo Nordisk

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026 email from Novo Nordisk

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions email from Novo Nordisk

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026 email from Novo Nordisk

Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care email from Novo Nordisk

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions email from Novo Nordisk

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke email from Novo Nordisk

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) email from Novo Nordisk

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class email from Novo Nordisk

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026 email from Novo Nordisk

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons email from Novo Nordisk

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity email from Novo Nordisk

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

Explore styles used by Novo Nordisk

Light Mode
Text Heavy
Health, Fitness & Wellness
Consideration
Newsletter Subscribers
Newsletter
Awareness
Classic
New Product Launch
Retention
Corporate
Summer